Cotinga Pharmaceuticals Ret. on equity
What is the Ret. on equity of Cotinga Pharmaceuticals?
The Ret. on equity of Cotinga Pharmaceuticals, Inc. is 91.05%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on TSXV compared to Cotinga Pharmaceuticals
What does Cotinga Pharmaceuticals do?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Companies with ret. on equity similar to Cotinga Pharmaceuticals
- Eramet SA has Ret. on equity of 90.29%
- Eramet SA has Ret. on equity of 90.29%
- MX Gold has Ret. on equity of 90.37%
- Sysco has Ret. on equity of 90.53%
- Persta Resources has Ret. on equity of 90.73%
- Dynavax Technologies has Ret. on equity of 90.76%
- Cotinga Pharmaceuticals has Ret. on equity of 91.05%
- GNC has Ret. on equity of 91.72%
- InZinc Mining has Ret. on equity of 91.77%
- StrikeForce Technologies has Ret. on equity of 91.78%
- Sysco has Ret. on equity of 92.10%
- AgeX Therapeutics Inc has Ret. on equity of 92.32%
- SPORTTOTAL AG has Ret. on equity of 92.35%